COPB2 and glioma: Univariate and multivariate Cox analyses showed that COPB2 may be a promising biomarker for glioma prognosis while a GSEA using TCGA data revealed that some inflammation‐ and immunity‐related pathways and other signaling pathways in cancer are differentially enriched in the COPB2 high expression phenotype.